Skip to main content
Premium Trial:

Request an Annual Quote

Roche's Dreismann Joins ChondroGene's Board; Radany Replaces Collamer as CEO of HTG; EA Taps Lowe for QA; and Others

NEW YORK (GenomeWeb News) – ChondroGene has appointed former Roche CEO Heiner Dreismann to its board of directors.
 
Before being appointed CEO, Dreismann held senior positions within Roche Diagnostics in the areas of global business development, business unit manager for PCR and microbiology, as well as R&D positions in microbiology and infectious diseases, and in manufacturing.
 
He said ChondroGene "is developing a truly revolutionary approach to molecular diagnostics," and the said the firm’s Sentinel Principle platform “enables timely, cost effective generation of biomarker content.”
 

 
William Radany has joined HTG as CEO. He replaces Kirk Collamer, who will remain with the company as CFO.
 
Radany joins the firm from Chemicon International. Prior to that, he was chief business officer at Xencor and served as vice president of drug discovery programs at both Caliper Technologies and Stratagene and president of Biacore.
 
Radany holds a BS in cell biology from Colorado State University and a PhD in biochemistry/physiology from the University of Wyoming.
 

 
Expression Analysis has hired Raisa Lowe as director of quality assurance. Raisa will be responsible for implementing quality initiatives at the company, including continued compliance to Good Laboratory Practices, Good Clinical Practices, and compliance with the Clinical Laboratory Improvement Amendment.
 
Raisa previously held quality assurance and compliance positions at Wellstat Biologics and Therapeutics, Diosynth RTP, and Compliance Quest.
 
Raisa has a BS in biology from the Interamerican University of Puerto Rico and an MS in biotechnology from Johns Hopkins University.
 

 
Proteopure has hired Juan Herrero as vice president of marketing and business development.
 
Herrero was previously an executive associate with the Pittsburgh Life Sciences Greenhouse. Prior to that, he served as vice president of life science and drug discovery at Fisher Scientific International. He also held several positions at AxCell Biosciences, including assistant director of molecular biology and senior director of operations.
 
Herrero holds a PhD in microbiology and molecular genetics, a masters degree in molecular biology, and an MBA.
 

 
Mirus Bio has appointed Scott Rose as vice president of finance and administration. Rose replaces Joseph Williams, who retired and plans to relocate his family to the West Coast, Mirus said.
 
Rose, a CPA, has an MBA with a specialization in information systems from the University of Wisconsin-Parkside.
 

 
Solvo Biotechnology has appointed Karl Kuchler to its strategic advisory board. Kuchler is associate professor of molecular genetics at the Medical University of Vienna.
 

 
Enterprise Analysis Corporation has promoted Susan Farber and Mark Hughes to vice president.
 
Farber will focus on EAC’s worldwide consulting and market research operations and manage the next phase of expansion of EAC’s international channel-checking and contact database.
 
Hughes, meantime, will be responsible for EAC’s strategic consulting practice. He will monitor emerging medical and life science research, the diagnostic markets, and changes in the practice of medicine.
 

 
Protagen has hired Jens Beator to oversee its new Protein Biochips unit.
 
Beator, 43, comes to Protagen from Whatman, where he was most recently director of business development
 
His duties at Protagen will be to further develop the firm’s UNIchip product line, introduced in September 2005.
 

Illumina spokesman Bill Craumer has left the company to join Isis Pharmaceuticals.
 
Craumer, in an e-mail, said he spent “six wonderful years with Illumina” but that he’d “always wanted to move downstream into the therapeutic space, and this is a wonderful opportunity.”

Isis, located in Carlsbad, Calif., just up the coast from Illumina’s San Diego headquarters, has a technology that discovers drugs focused on RNA targets in the areas of cardiovascular, metabolic, inflammatory diseases, and cancer, according to Craumer.  

 
He said the company plans to commercialize “an integrated biosensor system for use in disease surveillance, infectious disease research and diagnostics.”
 

Waters CEO Doug Berthiaume has given a $5 million award to the Isenberg School of Management at the University of Massachusetts Amherst.
 
The funds will help kick off a $350 million capital campaign, UMass said in a statement.
 

 
Guillermo Herrera has joined Spectral Diagnostics’ board of directors. Herrera was senior vice president of international operations at Abbott Laboratories and president of Abbott International. He is currently president and CEO of NeoPharm.
 

 
Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

 

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.